Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress

 Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress

Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress

Shots:

  • The P-II study involves evaluating the iptacopan vs PBO in 112 patients with IgAN. The new interim results of the P- II study in C3G will also be presented at ERA-EDTA Congress
  • The study met its 1EP i.e @ 90days, reduction in proteinuria as measured by 24hrs. UPCR, 23% reduction in proteinuria at the highest dose (200mg, bid), stabilized renal function as assessed by eGFR. The therapy showed favorable safety & tolerability profile
  • The P-III APPLAUSE trial is underway whereas the company plans to initiate P-III studies in other renal indications. The therapy has received EMA’s ODD in IgAN, ODD from the FDA & EMA in C3G & PNH, FDA’s BTD in PNH & EMA’s PRIME designation for C3G

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post